Evaluation of limited sampling strategies for tacrolimus

ObjectiveIn literature, a great diversity of limited sampling strategies (LSS) have been recommended for tacrolimus monitoring, however proper validation of these strategies to accurately predict the area under the time concentration curve (AUC0–12) is limited. The aim of this study was to determine whether these LSS might be useful for AUC prediction of other patient populations.MethodsThe LSS from literature studied were based on regression equations or on Bayesian fitting using MWPHARM 3.50 (Mediware, Groningen, the Netherlands). The performance was evaluated on 24 of these LSS in our population of 37 renal transplant patients with known AUCs. The results were also compared with the predictability of the regression equation based on the trough concentrations C0 and C12 of these 37 patients. Criterion was an absolute prediction error (APE) that differed less than 15% from the complete AUC0–12 calculated by the trapezoidal rule.ResultsThirteen of the 18 (72%) LSS based on regression analysis were capable of predicting at least 90% of the 37 individual AUC0–12 within an APE of 15%. Additionally, all but three LSS examined gave a better prediction of the complete AUC0–12 in comparison with the trough concentrations C0 or C12 (mean 62%). All six LSS based on Bayesian fitting predicted <90% of the 37 complete AUC0–12 correctly (mean 67%).ConclusionsThe present study indicated that implementation of LSS based on regression analysis could produce satisfactory predictions although careful evaluation is necessary.

[1]  C. Staatz,et al.  Comparison of an ELISA and an LC/MS/MS Method for Measuring Tacrolimus Concentrations and Making Dosage Decisions in Transplant Recipients , 2002, Therapeutic drug monitoring.

[2]  D. Min,et al.  An abbreviated area-under-the-curve monitoring for tacrolimus in patients with liver transplants. , 1998, Therapeutic drug monitoring.

[3]  R. Kershner,et al.  Relationship of FK506 whole blood concentrations and efficacy and toxicity after liver and kidney transplantation. , 1996, Transplantation.

[4]  S. Takahara,et al.  Monitoring of FK 506 blood levels in kidney transplant recipients. , 1994, Transplantation proceedings.

[5]  C. Cantarell,et al.  Evaluation of a Limited Sampling Strategy to Estimate Area Under the Curve of Tacrolimus in Adult Renal Transplant Patients , 2005, Therapeutic drug monitoring.

[6]  J. M. Arizón del Prado,et al.  Clinical pharmacokinetics of tacrolimus in heart transplantation: new strategies of monitoring. , 2003, Transplantation proceedings.

[7]  G. Klintmalm,et al.  Whole blood and plasma levels of FK 506 after liver transplantation: correlation with toxicity. , 1994, Transplantation proceedings.

[8]  T. Pisitkun,et al.  The roles of C4 and AUC0-4 in monitoring of tacrolimus in stable kidney transplant patients. , 2002, Transplantation proceedings.

[9]  A Johnston,et al.  Limited Sampling Strategies for Estimating Cyclosporin Area Under the Concentration–Time Curve: Review of Current Algorithms , 2001, Therapeutic drug monitoring.

[10]  J. Proost.  Adaptive control of drug dosage regimens using maximum a posteriori probability Bayesian fitting. , 1995, International journal of clinical pharmacology and therapeutics.

[11]  Mary H. H. Ensom,et al.  Beyond Cyclosporine: A Systematic Review of Limited Sampling Strategies for Other Immunosuppressants , 2006, Therapeutic drug monitoring.

[12]  V. Armstrong,et al.  Pharmacokinetics of tacrolimus primary immunosuppression in kidney transplant recipients. , 2001, Transplantation proceedings.

[13]  R. Borrows,et al.  Tacrolimus monitoring in renal transplantation: a comparison between high-performance liquid chromatography and immunoassay. , 2005, Transplantation proceedings.

[14]  J. V. van Hooff,et al.  Trough levels of tacrolimus. , 2002, Therapeutic drug monitoring.

[15]  C. Shek,et al.  Abbreviated tacrolimus area-under-the-curve monitoring for renal transplant recipients. , 2000, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[16]  J. D. de Fijter,et al.  AUC-guided dosing of tacrolimus prevents progressive systemic overexposure in renal transplant recipients. , 2005, Kidney international.

[17]  P. Mcmaster,et al.  Therapeutic Drug Monitoring of Tacrolimus in Clinical Transplantation , 1995, Therapeutic drug monitoring.

[18]  R. Lechler,et al.  Do cyclosporin proffles provide useful information in the management of renal transplant recipients , 1996 .

[19]  R. Pichlmayr,et al.  The use of plasma levels for FK 506 dosing in liver-grafted patients , 1994, Transplant international : official journal of the European Society for Organ Transplantation.

[20]  C. Staatz,et al.  Clinical Pharmacokinetics and Pharmacodynamics of Tacrolimus in Solid Organ Transplantation , 2004, Clinical pharmacokinetics.

[21]  Lewis B. Sheiner,et al.  Some suggestions for measuring predictive performance , 1981, Journal of Pharmacokinetics and Biopharmaceutics.

[22]  U. Christians,et al.  A Risk-Benefit Assessment of Tacrolimus in Transplantation , 1995, Drug safety.

[23]  R. Portman,et al.  A limited sampling strategy for the estimation of eight-hour neoral areas under the curve in renal transplantation. , 1998, Therapeutic drug monitoring.

[24]  J. Hooff,et al.  Low systemic exposure to tacrolimus correlates with acute rejection. , 1999, Transplantation proceedings.

[25]  S. Takahara,et al.  Clinical evaluation of trough levels and area under the curve in cyclosporine- and FK 506-treated kidney transplant recipients. , 1994, Transplantation proceedings.

[26]  B. Maes,et al.  Time-Related Clinical Determinants of Long-Term Tacrolimus Pharmacokinetics in Combination Therapy with Mycophenolic Acid and Corticosteroids , 2004, Clinical pharmacokinetics.

[27]  M. Kamler,et al.  Tacrolimus pharmacokinetics in lung transplantation: new strategies for monitoring. , 2005, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[28]  B. Kahan,et al.  Pharmacological surrogates of allograft outcome. , 2000, Annals of transplantation.

[29]  S. Soldin,et al.  IMx tacrolimus II assay: is it reliable at low blood concentrations? A comparison with tandem MS/MS. , 2002, Clinical biochemistry.

[30]  C. Gonde,et al.  Low hematocrit and serum albumin concentrations underlie the overestimation of tacrolimus concentrations by microparticle enzyme immunoassay versus liquid chromatography-tandem mass spectrometry. , 2005, Clinical chemistry.

[31]  A. Matas,et al.  An open-label, concentration-ranging trial of FK506 in primary kidney transplantation: a report of the United States Multicenter FK506 Kidney Transplant Group. , 1996, Transplantation.